Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Renal effects of SGLT2 inhibitors
Josselin Nespoux, Volker Vallon
Current Opinion in Nephrology & Hypertension (2019) Vol. 29, Iss. 2, pp. 190-198
Open Access | Times Cited: 103

Showing 1-25 of 103 citing articles:

Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
André Scheen
Nature Reviews Endocrinology (2020) Vol. 16, Iss. 10, pp. 556-577
Closed Access | Times Cited: 229
Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy
Yu Ho Lee, Sang Hoon Kim, Jun Kang, et al.
AJP Renal Physiology (2019) Vol. 317, Iss. 4, pp. F767-F780
Open Access | Times Cited: 155
SGLT2 inhibitors: Beyond glycemic control
Irtiza Hasan, Tasnuva Rashid, Vishal Jaikaransingh, et al.
Journal of Clinical & Translational Endocrinology (2024) Vol. 35, pp. 100335-100335
Open Access | Times Cited: 16
Integrated Management of Cardiovascular–Renal–Hepatic–Metabolic Syndrome: Expanding Roles of SGLT2is, GLP-1RAs, and GIP/GLP-1-RAs
Nikolaos Theodorakis, Maria Nikolaou
Biomedicines (2025) Vol. 13, Iss. 1, pp. 135-135
Open Access | Times Cited: 10
New users of sodium-glucose cotransporter 2 inhibitors are at low risk of incident pancreatic cancer: a nationwide population-based cohort study
Yun Kyung Cho, Sehee Kim, Myeong‐Jin Kim, et al.
Diabetes & Metabolism (2025), pp. 101605-101605
Closed Access | Times Cited: 2
Glucose transporters in the kidney in health and disease
Volker Vallon
Pflügers Archiv - European Journal of Physiology (2020) Vol. 472, Iss. 9, pp. 1345-1370
Open Access | Times Cited: 102
Dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats
Krit Jaikumkao, Anchalee Pongchaidecha, Nuttawud Chueakula, et al.
Diabetes Obesity and Metabolism (2018) Vol. 20, Iss. 11, pp. 2617-2626
Closed Access | Times Cited: 89
Sodium-coupled glucose transport, the SLC5 family, and therapeutically relevant inhibitors: from molecular discovery to clinical application
Gergely Gyimesi, Jonai Pujol‐Giménez, Yoshikatsu Kanai, et al.
Pflügers Archiv - European Journal of Physiology (2020) Vol. 472, Iss. 9, pp. 1177-1206
Open Access | Times Cited: 88
Acute and Chronic Effects of SGLT2 Inhibitor Empagliflozin on Renal Oxygenation and Blood Pressure Control in Nondiabetic Normotensive Subjects: A Randomized, Placebo‐Controlled Trial
Anne Zanchi, Michel Burnier, Müller Me, et al.
Journal of the American Heart Association (2020) Vol. 9, Iss. 13
Open Access | Times Cited: 83
Function of Uric Acid Transporters and Their Inhibitors in Hyperuricaemia
Haolu Sun, Yi-wan Wu, He-ge Bian, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 66
Renoprotective mechanisms of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease
Sreenithya Ravindran, Shankar Munusamy
Journal of Cellular Physiology (2021) Vol. 237, Iss. 2, pp. 1182-1205
Closed Access | Times Cited: 61
Canagliflozin protects against cisplatin-induced acute kidney injury by AMPK-mediated autophagy in renal proximal tubular cells
Cheol Ho Park, Bin Lee, Myeonggil Han, et al.
Cell Death Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 42
Dapagliflozin Alleviates Diabetic Kidney Disease via Hypoxia Inducible Factor 1α/Heme Oxygenase 1-Mediated Ferroptosis
Yi-hui Wang, Dong‐Yuan Chang, Ming‐Hui Zhao, et al.
Antioxidants and Redox Signaling (2023) Vol. 40, Iss. 7-9, pp. 492-509
Closed Access | Times Cited: 27
The clinical benefits of sodium–glucose cotransporter type 2 inhibitors in people with gout
Chio Yokose, Natalie McCormick, Abhishek Abhishek, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 4, pp. 216-231
Closed Access | Times Cited: 13
The alleviative effects of canagliflozin on imiquimod-induced mouse model of psoriasis-like inflammation
H. Salman, Adeeb A. Al-Zubaidy, Alaa Hamza Abbas, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2024)
Closed Access | Times Cited: 13
Efficacy and Safety of Efpeglenatide in Patients With Type 2 Diabetes and Obesity: A Systematic Review
Neha Narayan, Tejaswi Vadde, Maharshikumar Sandesara, et al.
Cureus (2025)
Open Access | Times Cited: 1
The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease
Ken Ohara, Takahiro Masuda, Masato Morinari, et al.
Diabetology & Metabolic Syndrome (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 52
Interplay between extracellular matrix components and cellular and molecular mechanisms in kidney fibrosis
Sandra Rayego‐Mateos, Sofía Campillo, Raúl R. Rodrigues-Díez, et al.
Clinical Science (2021) Vol. 135, Iss. 16, pp. 1999-2029
Closed Access | Times Cited: 47
Do the Current Guidelines for Heart Failure Diagnosis and Treatment Fit with Clinical Complexity?
Paolo Severino, Andrea D’Amato, Silvia Prosperi, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 3, pp. 857-857
Open Access | Times Cited: 32
Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial
Frederik Husum Mårup, Martin Bjergskov Thomsen, Henrik Birn
Clinical Kidney Journal (2023) Vol. 17, Iss. 1
Open Access | Times Cited: 17
Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy
Giovanna Castoldi, Raffaella Carletti, Silvia Ippolito, et al.
Acta Diabetologica (2021)
Open Access | Times Cited: 34
The Effect of SGLT2 Inhibitors on the Development of Contrast-Induced Nephropathy in Diabetic Patients with Non-ST Segment Elevation Myocardial Infarction
Uğur Özkan, Muhammet Gürdoğan
Medicina (2023) Vol. 59, Iss. 3, pp. 505-505
Open Access | Times Cited: 15
Uric acid transport, transporters, and their pharmacological targeting
Emmanuel A. Adomako, Orson W. Moe
Acta Physiologica (2023) Vol. 238, Iss. 2
Open Access | Times Cited: 14
Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis
Eun Sil Koh, Gheun‐Ho Kim, Sungjin Chung
Endocrinology and Metabolism (2023) Vol. 38, Iss. 4, pp. 359-372
Open Access | Times Cited: 13
SGLT2 knockdown restores the Th17/Treg balance and suppresses diabetic nephropathy in db/db mice by regulating SGK1 via Na+
Dan Wang, Qian Zhang, Wenhui Dong, et al.
Molecular and Cellular Endocrinology (2024) Vol. 584, pp. 112156-112156
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top